Literature DB >> 30118716

Circulating APP, NCAM and Aβ serve as biomarkers for Alzheimer's disease.

Keping Chen1, Tianli Gao2, Zhimao Bai3, Zuanning Yuan4.   

Abstract

Alzheimer's disease (AD) is the most common neurodegenerative disease and the early diagnosis and intervention are important for valid treatment of AD. However, there are few biomarkers for the diagnosis and monitoring of AD. In the present study, circulating APP, NCAM, Aβ40, and Aβ42 were measured in order to identify which marker or combination of markers could be useful, cost-effective and noninvasive biomarkers for diagnosing and continuously monitoring AD. The results showed that circulating APP, NCAM, Aβ40, and Aβ42 were different between the AD group and the control group. Importantly, the combination of the four biomarkers had the highest AUC (0.997) with the highest sensitivity (98.5). Therefore, circulating APP, NCAM, Aβ40, and Aβ42 can be used as desirable biomarkers for AD diagnosis and monitoring.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-precursor protein; Circulating biomarker; Neural cell adhesion molecule; β-Amyloid

Mesh:

Substances:

Year:  2018        PMID: 30118716     DOI: 10.1016/j.brainres.2018.08.015

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

1.  Distinct and dementia-related synaptopathy in the hippocampus after military blast exposures.

Authors:  Michael F Almeida; Thuvan Piehler; Kelly E Carstens; Meilan Zhao; Mahsa Samadi; Serena M Dudek; Christopher J Norton; Catherine M Parisian; Karen L G Farizatto; Ben A Bahr
Journal:  Brain Pathol       Date:  2021-02-24       Impact factor: 7.611

2.  Association between inflammatory biomarkers and cognitive aging.

Authors:  Yuan Fang; Margaret F Doyle; Jiachen Chen; Michael L Alosco; Jesse Mez; Claudia L Satizabal; Wei Qiao Qiu; Joanne M Murabito; Kathryn L Lunetta
Journal:  PLoS One       Date:  2022-09-09       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.